Abstracts tagged "outcome measures and vasculitis"

Abstract Number: 2967 • 2016 ACR/ARHP Annual Meeting
Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise
Alexa Meara¹, Yesim Ozguler², Alfred Mahr³, Haner Direskeneli⁴, Ahmet Gul⁵, Yusuf Yazici⁶, Hasan Yazici², Peter A. Merkel⁷ and Gulen Hatemi², ¹Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Hospital Saint-Louis, Paris, France, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁶Rheumatology, New York University Medical Center, La Jolla, CA, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: An unmet need for reliable, validated, and widely accepted outcome measures for trials in BehetÕs syndrome (BS) was identified through: i) a systematic review;…
Abstract Number: 873 • 2015 ACR/ARHP Annual Meeting
The ANCA-Vasculitis Index of Damage (AVID): Performance of a New Damage Instrument
Eli Miloslavsky^1,2, Na Lu³, Sebastian Unizony³, Hyon K. Choi³, Peter A. Merkel⁴, Philip Seo⁵, Robert F. Spiera⁶, Carol A. Langford⁷, Gary S. Hoffman⁷, Cees Kallenberg⁸, E. William St.Clair⁹, Nadia Tchao¹⁰, Fernando Fervenza¹¹, Paul A. Monach¹², Ulrich Specks¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, ⁹Rheumatology and Immunology, Duke University, Durham, NC, ¹⁰ITN, San Francisco, CA, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Damage related to active disease or its treatment is an important outcome measure in ANCA-associated vasculitis (AAV). The Vasculitis Damage Index (VDI), the principal…
Abstract Number: 871 • 2015 ACR/ARHP Annual Meeting
Clinicians’ Perspective on Aspects of ANCA-Associated Vasculitis That Influence Patients’ Function and General Health: A Delphi Exercise Based on the International Classification of Function, Disability and Health
Nataliya Milman¹, Peter Tugwell², Annelies Boonen³ and Peter A. Merkel⁴, ¹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ²Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a multisystem condition that results in significant level of morbidity and functional limitations for many patients. Previous studies showed that…
Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Joanna Robson¹, Helen Doll², Ravi Suppiah³, Oliver Flossmann⁴, Lorraine Harper⁵, Peter Hoglund⁶, David Jayne⁷, Alfred Mahr⁸, Kerstin Westman⁹ and Raashid A. Luqmani¹⁰, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²Department of Population Health, University of East Anglia, Norwich, United Kingdom, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, ⁵Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁶Competence Centre fo Clinical Research, Skane University Hospital, Lund, Sweden, ⁷Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁸Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ⁹Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…
Abstract Number: 1524 • 2012 ACR/ARHP Annual Meeting
The Use of the International Classification of Function, Disability and Health As a Conceptual Framework for Comparison of the Content of Core Outcome Instruments with the Patient Perspective in Vasculitis
Nataliya Milman¹, Peter A. Merkel², Annelies Boonen³, Lee Strunin⁴, Ryan Borg⁴ and Peter Tugwell⁵, ¹Rheumatology, Ottawa Hospital, Riverside Campus, Ottawa, ON, Canada, ²University of Pennsylvania, Philadelphia, PA, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Community Health Sciences, Boston University School of Public Health, Boston, MA, ⁵Institute of Population Health, Center For Global Health, University of Ottawa, Ottawa General Hospital, Ottawa, ON, Canada
Background/Purpose: The International Classification of Functioning, Disability and Health (ICF) is a general health model endorsed by the World Health Organization. It describes health along…
Abstract Number: 1527 • 2012 ACR/ARHP Annual Meeting
Patient Global Assessments for Disease Activity Are Predictive of Future Flare in Granulomatosis with Polyangiitis (Wegener’s)
Gunnar Tomasson¹, John C. Davis Jr.², Gary S. Hoffman³, W. Joseph McCune⁴, Ulrich Specks⁵, Robert F. Spiera⁶, E. William St. Clair⁷, John H. Stone⁸ and Peter A. Merkel⁹, ¹Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland, ²Genentech, Inc, South San Francisco, CA, ³Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine, Duke University Medical Center, Durham, NC, ⁸Rheumatology, Massachusetts General Hospital, Boston, MA, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: In granulomatosis with polyangiitis GPA), disease activity is assessed by physician-based measures. In some other rheumatic diseases, such as rheumatoid arthritis (RA) and ankylosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].